Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: Follow-up through Month 48 in a Phase III randomized study

Mark H. Einstein, Myron J. Levin, Archana Chatterjee, Nahida Chakhtoura, Peter Takacs, Grégory Catteau, Francis J. Dessy, Philippe Moris, Lan Lin, Frank Struyf, Gary Dubin, Mark Blatter, Christopher V. Chambers, Marina Fernandez, Bradley Fox, David L. Fried, Sidney A. Funk, Cheryl A. Hansen, James A. Hedrick, Bethany HoffmanTerry D. Klein, Jacob Lalezari, Michael J. Noss, James H. Silverblatt, Rhoda S. Sperling, Karen G. Swenson, Troy Thompson, Mark Turner, Michael W. Warren, Robert Yoachim

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Fingerprint

Dive into the research topics of 'Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: Follow-up through Month 48 in a Phase III randomized study'. Together they form a unique fingerprint.

Medicine & Life Sciences